DXCM faces an FDA warning over manufacturing issues, but operations remain unaffected. However, supply-chain risks and rising ...

not a long-term thing that we will have to do because we see that if they have that CGM on, it’s more reliable,” said Dr. Bruner-Hill In a post on Dexcom’s website, the company said if you are unable ...

The company does not expect the warning letter to materially impact its manufacturing capacity, sales or ability to seek ...

Trinity Biotech (Nasdaq:TRIB) today announced the next stage of its transformation plan as it looks to bring a CGM to market.

The FDA has cleared Dexcom’s Stelo as the first continuous glucose monitoring (CGM) device that does not ... for one two-week sensor and £300 for four. There are more than 25 million type ...

Any time we try a healthy new way of eating, it’s easy for doubt to creep in. Is it really working? Is it worth it? Does it ...

A recently published study highlighted the strong performance of the Insulet (Nasdaq:PODD) Omnipod 5 in children and young ...

DexCom said that on Tuesday it received a warning letter from the U.S. FDA following inspections at its facilities in San Diego, Calif., and Mesa, Ariz. related to concerns about manufacturing ...

DexCom (NASDAQ:DXCM), known for its continuous glucose monitoring (CGM) systems, recently unveiled its Q4 2024 earnings report on Feb. 13, 2025. This release highlighted an 8% growth in revenue ...

DexCom projects 2025 revenue of $4.6 billion, representing 14% growth. This forecast assumes strong demand for CGM systems ... the impact of the 15-day G7 sensor. COO Jake Leach expressed ...

Stelo CGM Launch: In August 2024, DexCom announced the commercial launch of Stelo CGM, the first over-the-counter glucose sensor in the U.S. for non-insulin using Type 2 diabetes and prediabetes ...